Lucid Diagnostics Stock Analysis

Lucid Stock Analysis Notes

About 35.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.77. Lucid Diagnostics had not issued any dividends in recent years. Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. To find out more about Lucid Diagnostics contact Lishan MD at 917 813 1828 or learn more at https://www.luciddx.com.

Lucid Diagnostics Investment Alerts

Lucid Largest EPS Surprises

View All Earnings Estimates

Lucid Stock Institutional Investors

Note, although Lucid Diagnostics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lucid Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 159.94 M.

Lucid Profitablity

Management Efficiency

Lucid Diagnostics has return on total asset (ROA) of (0.7917) % which means that it has lost $0.7917 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3124) %, meaning that it created substantial loss on money invested by shareholders. Lucid Diagnostics' management efficiency ratios could be used to measure how well Lucid Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 9, 2026, Return On Tangible Assets is expected to decline to -1.44. The current year's Return On Capital Employed is expected to grow to -5.48. The current year's Net Tangible Assets is expected to grow to about 23.7 M, whereas Total Assets are forecasted to decline to about 24 M.

Technical Drivers

As of the 9th of February, Lucid Diagnostics secures the Downside Deviation of 3.51, risk adjusted performance of 0.0247, and Mean Deviation of 2.69. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lucid Diagnostics, as well as the relationship between them. Please verify Lucid Diagnostics coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Lucid Diagnostics is priced some-what accurately, providing market reflects its recent price of 1.23 per share. Given that Lucid Diagnostics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Lucid Diagnostics Price Movement Analysis

Lucid Diagnostics Insider Trading Activities

Lucid Diagnostics Outstanding Bonds

Lucid Diagnostics Predictive Daily Indicators

Lucid Diagnostics Forecast Models

Lucid Diagnostics' time-series forecasting models are one of many Lucid Diagnostics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lucid Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Lucid Diagnostics Bond Ratings

Lucid Diagnostics financial ratings play a critical role in determining how much Lucid Diagnostics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lucid Diagnostics' borrowing costs.

Lucid Diagnostics Debt to Cash Allocation

Lucid Diagnostics currently holds 21.25 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Lucid Diagnostics has a current ratio of 4.46, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lucid Diagnostics' use of debt, we should always consider it together with its cash and equity.

Lucid Diagnostics Total Assets Over Time

Lucid Diagnostics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Lucid Diagnostics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Lucid Diagnostics Debt Ratio

35.0

It looks as if about 65% of Lucid Diagnostics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lucid Diagnostics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lucid Diagnostics, which in turn will lower the firm's financial flexibility.

Lucid Diagnostics Corporate Bonds Issued

Lucid Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lucid Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lucid shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lucid Diagnostics. By using and applying Lucid Stock analysis, traders can create a robust methodology for identifying Lucid entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lucid analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lucid analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Lucid Diagnostics stock analysis indicators help investors evaluate how Lucid Diagnostics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lucid Diagnostics shares will generate the highest return on investment. By understating and applying Lucid Diagnostics stock analysis, traders can identify Lucid Diagnostics position entry and exit signals to maximize returns.

When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.